Dataset Information


PiR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair.

ABSTRACT: Resistance to doxorubicin (DOX) is an obstacle to successful sarcoma treatment and a cause of tumor relapse, with the underlying molecular mechanism still unknown. PIWI-interacting RNAs (piRNAs) have been shown to enhance patient outcomes in cancers. However, there are few or no reports on piRNAs affecting chemotherapy in cancers, including fibrosarcoma. The current study aims to investigate the relationship between piR-39980 and DOX resistance and the underlying mechanisms. We reveal that piR-39980 is less expressed in DOX-resistant HT1080 (HT1080/DOX) fibrosarcoma cells. Our results show that inhibition of piR-39980 in parental HT1080 cells induces DOX resistance by attenuating intracellular DOX accumulation, DOX-induced apoptosis, and anti-proliferative effects. Its overexpression in HT1080/DOX cells, on the other hand, increases DOX sensitivity by promoting intracellular DOX accumulation, DNA damage, and apoptosis. The dual-luciferase reporter assay indicates that piR-39980 negatively regulates RRM2 and CYP1A2 via direct binding to their 3'UTRs. Furthermore, overexpressing RRM2 induces DOX resistance of HT1080 cells by rescuing DOX-induced DNA damage by promoting DNA repair, whereas CYP1A2 confers resistance by decreasing intracellular DOX accumulation, which piR-39980 restores. This study reveals that piR-39980 could reduce fibrosarcoma resistance to DOX by modulating RRM2 and CYP1A2, implying that piRNA can be used in combination with DOX.

PROVIDER: S-EPMC8605029 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC5984882 | BioStudies
| S-EPMC7570921 | BioStudies
| S-EPMC4156787 | BioStudies
| S-EPMC8290475 | BioStudies
| S-EPMC8447905 | BioStudies
| S-EPMC5470966 | BioStudies
| S-EPMC7593925 | BioStudies
| S-EPMC7288952 | BioStudies
| S-EPMC5157154 | BioStudies
| E-GEOD-48673 | BioStudies